EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Clinical trials for EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION trials appear
Sign up with your email to follow new studies for EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug EPI-326 enters human testing for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…
Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Real-World data sought on common lung cancer drug combo
Knowledge-focused Recruiting nowThis study is not testing a new drug but watching how well standard treatments work for people with a specific type of lung cancer (EGFR-mutated NSCLC) in everyday medical practice. About 538 adults with advanced lung cancer will be followed to see how long they live without the …
Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Sponsor: PrECOG, LLC. • Aim: Knowledge-focused
Last updated May 15, 2026 11:52 UTC